Forge Life Science

FORGE Life Science was founded on breakthrough discoveries made at Princeton University. Whereas immuno-oncology drugs engage the patient’s immune system to fight cancer, FORGE antivirals engage the cell’s intrinsic immunity to defend against infection. FORGE’s vision is to develop first-in-class antivirals that are safe, address the problem of acquired drug-resistance, and provide unique broad-spectrum treatment options. This will transform the practice of medicine because FORGE products will address the infectious disease condition as opposed to targeting a specific virus-type. Imagine being prescribed a safe, broad-spectrum antiviral, without the risk of acquired drug-resistance, based on symptom presentation, and prior to diagnostic confirmation of infecting virus-type. Our highly-innovative products are early-stage, yet we bring tangible solutions to solve real clinical challenges and unmet medical need.